5sxx Citations

Isonicotinic acid hydrazide conversion to Isonicotinyl-NAD by catalase-peroxidases.

J Biol Chem 285 26662-73 (2010)
Related entries: 5sxq, 5sxr, 5sxs, 5sxt, 5sxw

Cited: 29 times
EuropePMC logo PMID: 20554537

Abstract

Activation of the pro-drug isoniazid (INH) as an anti-tubercular drug in Mycobacterium tuberculosis involves its conversion to isonicotinyl-NAD, a reaction that requires the catalase-peroxidase KatG. This report shows that the reaction proceeds in the absence of KatG at a slow rate in a mixture of INH, NAD(+), Mn(2+), and O(2), and that the inclusion of KatG increases the rate by >7 times. Superoxide, generated by either Mn(2+)- or KatG-catalyzed reduction of O(2), is an essential intermediate in the reaction. Elimination of the peroxidatic process by mutation slows the rate of reaction by 60% revealing that the peroxidatic process enhances, but is not essential for isonicotinyl-NAD formation. The isonicotinyl-NAD(*+) radical is identified as a reaction intermediate, and its reduction by superoxide is proposed. Binding sites for INH and its co-substrate, NAD(+), are identified for the first time in crystal complexes of Burkholderia pseudomallei catalase-peroxidase with INH and NAD(+) grown by co-crystallization. The best defined INH binding sites were identified, one in each subunit, on the opposite side of the protein from the entrance to the heme cavity in a funnel-shaped channel. The NAD(+) binding site is approximately 20 A from the entrance to the heme cavity and involves interactions primarily with the AMP portion of the molecule in agreement with the NMR saturation transfer difference results.

Reviews citing this publication (6)

  1. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Brown-Elliott BA, Nash KA, Wallace RJ. Clin Microbiol Rev 25 545-582 (2012)
  2. Why do bacteria use so many enzymes to scavenge hydrogen peroxide? Mishra S, Imlay J. Arch Biochem Biophys 525 145-160 (2012)
  3. Thirty years of heme catalases structural biology. Díaz A, Loewen PC, Fita I, Carpena X. Arch Biochem Biophys 525 102-110 (2012)
  4. Catalase in peroxidase clothing: Interdependent cooperation of two cofactors in the catalytic versatility of KatG. Njuma OJ, Ndontsa EN, Goodwin DC. Arch Biochem Biophys 544 27-39 (2014)
  5. Update of Antitubercular Prodrugs from a Molecular Perspective: Mechanisms of Action, Bioactivation Pathways, and Associated Resistance. Laborde J, Deraeve C, Bernardes-Génisson V. ChemMedChem 12 1657-1676 (2017)
  6. Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead. Tarashi S, Siadat SD, Fateh A. Biomed Res Int 2022 8168750 (2022)

Articles citing this publication (23)

  1. Organic hydroperoxide resistance protein and ergothioneine compensate for loss of mycothiol in Mycobacterium smegmatis mutants. Ta P, Buchmeier N, Newton GL, Rawat M, Fahey RC. J Bacteriol 193 1981-1990 (2011)
  2. Classic reaction kinetics can explain complex patterns of antibiotic action. Abel Zur Wiesch P, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, Cohen T. Sci Transl Med 7 287ra73 (2015)
  3. High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads. Wolf NM, Lee H, Choules MP, Pauli GF, Phansalkar R, Anderson JR, Gao W, Ren J, Santarsiero BD, Lee H, Cheng J, Jin YY, Ho NA, Duc NM, Suh JW, Abad-Zapatero C, Cho S. ACS Infect Dis 5 829-840 (2019)
  4. Identifying the elusive sites of tyrosyl radicals in cytochrome c peroxidase: implications for oxidation of substrates bound at a site remote from the heme. Miner KD, Pfister TD, Hosseinzadeh P, Karaduman N, Donald LJ, Loewen PC, Lu Y, Ivancich A. Biochemistry 53 3781-3789 (2014)
  5. Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies. Abel Zur Wiesch P, Clarelli F, Cohen T. PLoS Comput Biol 13 e1005321 (2017)
  6. Access channel residues Ser315 and Asp137 in Mycobacterium tuberculosis catalase-peroxidase (KatG) control peroxidatic activation of the pro-drug isoniazid. Zhao X, Hersleth HP, Zhu J, Andersson KK, Magliozzo RS. Chem Commun (Camb) 49 11650-11652 (2013)
  7. Unprecedented access of phenolic substrates to the heme active site of a catalase: substrate binding and peroxidase-like reactivity of Bacillus pumilus catalase monitored by X-ray crystallography and EPR spectroscopy. Loewen PC, Villanueva J, Switala J, Donald LJ, Ivancich A. Proteins 83 853-866 (2015)
  8. Using cryo-EM to understand antimycobacterial resistance in the catalase-peroxidase (KatG) from Mycobacterium tuberculosis. Munir A, Wilson MT, Hardwick SW, Chirgadze DY, Worrall JAR, Blundell TL, Chaplin AK. Structure 29 899-912.e4 (2021)
  9. Bioinformatics Identification of Drug Resistance-Associated Gene Pairs in Mycobacterium tuberculosis. Cui ZJ, Yang QY, Zhang HY, Zhu Q, Zhang QY. Int J Mol Sci 17 E1417 (2016)
  10. KatG-Mediated Oxidation Leading to Reduced Susceptibility of Bacteria to Kanamycin. Loewen PC, De Silva PM, Donald LJ, Switala J, Villanueva J, Fita I, Kumar A. ACS Omega 3 4213-4219 (2018)
  11. Stimulation of KatG catalase activity by peroxidatic electron donors. Ndontsa EN, Moore RL, Goodwin DC. Arch Biochem Biophys 525 215-222 (2012)
  12. [Fe(CN)5(isoniazid)](3-): an iron isoniazid complex with redox behavior implicated in tuberculosis therapy. Sousa EH, de Mesquita Vieira FG, Butler JS, Basso LA, Santiago DS, Diógenes IC, Lopes LG, Sadler PJ. J Inorg Biochem 140 236-244 (2014)
  13. The crystal structure of isoniazid-bound KatG catalase-peroxidase from Synechococcus elongatus PCC7942. Kamachi S, Hirabayashi K, Tamoi M, Shigeoka S, Tada T, Wada K. FEBS J 282 54-64 (2015)
  14. Mutual synergy between catalase and peroxidase activities of the bifunctional enzyme KatG is facilitated by electron hole-hopping within the enzyme. Njuma OJ, Davis I, Ndontsa EN, Krewall JR, Liu A, Goodwin DC. J Biol Chem 292 18408-18421 (2017)
  15. Crystal structure of the catalase-peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro-drug isoniazid. Kamachi S, Hirabayashi K, Tamoi M, Shigeoka S, Tada T, Wada K. FEBS Lett 589 131-137 (2015)
  16. Molecular investigation of active binding site of isoniazid (INH) and insight into resistance mechanism of S315T-MtKatG in Mycobacterium tuberculosis. Srivastava G, Tripathi S, Kumar A, Sharma A. Tuberculosis (Edinb) 105 18-27 (2017)
  17. High conformational stability of secreted eukaryotic catalase-peroxidases: answers from first crystal structure and unfolding studies. Zámocký M, García-Fernández Q, Gasselhuber B, Jakopitsch C, Furtmüller PG, Loewen PC, Fita I, Obinger C, Carpena X. J Biol Chem 287 32254-32262 (2012)
  18. Molecular dynamics-based investigation of InhA substrate binding loop for diverse biological activity of direct InhA inhibitors. Kumar V, Sobhia ME. J Biomol Struct Dyn 34 2434-2452 (2016)
  19. DFT study on the effect of proximal residues on the Mycobacterium tuberculosis catalase-peroxidase (katG) heme compound I intermediate and its bonding interaction with isoniazid. Reyes YIA, Franco FC. Phys Chem Chem Phys 21 16515-16525 (2019)
  20. Peroxidase improves the activity of catalase by preventing aggregation during TFE-induced denaturation. Furkan M, Rizvi A, Alam MT, Naeem A. J Biomol Struct Dyn 36 551-560 (2018)
  21. Reinvestigation of the structure-activity relationships of isoniazid. Hegde P, Boshoff HIM, Rusman Y, Aragaw WW, Salomon CE, Dick T, Aldrich CC. Tuberculosis (Edinb) 129 102100 (2021)
  22. In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis. Marquês JT, Frazão De Faria C, Reis M, Machado D, Santos S, Santos MDS, Viveiros M, Martins F, De Almeida RFM. Front Pharmacol 13 868545 (2022)
  23. Withdrawn Infect Disord Drug Targets (2012)